Neuland Laboratories Limited (NEULANDLAB) Fair Value & Analysis
Healthcare · IN · Market cap ₹244B (≈ $2.6B) · ISIN INE794A01010
What is Neuland Laboratories Limited really worth?
A solid business, but trading 279% above our fair value of ₹5,987.
Strengths
Risks
Fair value as of: Aug 23, 2026
From 17 valuation models · updated 13 days ago
Share price +13.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹7,802). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹4,191 to ₹7,802) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.
How to read this chart
60‑month range ₹963.46 – ₹23,661 · fair‑value band ₹4,191 – ₹7,802 · the ₹22,660 price screens above the ₹5,987 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 23, 2026.
Analysis
Neuland Laboratories Limited (NEULANDLAB) currently trades at ₹22,660, while our model-based Fair Value estimate is ₹5,987, implying the stock looks roughly 278.5% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹5,987 per share, and 0 of the 17 models we run sit above the ₹22,660 price. Bear case: the Asset-Based group reads lowest at ₹978.88, and 17 of the 17 models stay below the price. Evidence for this calculation is high.
Revenue grew 136.4% year over year. It earns a return on equity of 15.9%. The balance sheet holds a net cash position of ₹537M. The stock trades on a trailing P/E of 79.9. Fundamentals as of Aug 23, 2026
Our scenario range runs from ₹4,191 (bear case) to ₹7,802 (bull case); at ₹22,660, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 97% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −74%, NEULANDLAB screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹122.02 per share, which is 2.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 17 models by family
Widest divergence: Growth Earnings (₹5,987) versus Dividend Discount (₹206.43). Highest evidence: EPV (74).
Notify me when NEULANDLAB reaches fair value
Put NEULANDLAB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 89
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Neuland Laboratories Limited reported revenue of ₹20.2B in FY2026 versus ₹9.2B in FY2022, a compound +21.7%/yr. Reported net income was ₹3.6B in FY2026, compounding +54.5%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
of which total revenue +13.9 % · buybacks/dilution −3.3 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
NEULANDLAB screens 279% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Neuland Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Neuland Laboratories Limited (NEULANDLAB) overvalued or undervalued?
What is the fair value of NEULANDLAB?
What is the quality score of NEULANDLAB?
What is the net profit margin of NEULANDLAB?
Does Neuland Laboratories Limited pay a dividend?
Watch Neuland Laboratories Limited in the live analysis
One click puts Neuland Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.